On this episode of Not So Different, we reminisce about the major biosimilar news to come out of the rheumatology field during January 2023, including the launch of the first Humira (adalimumab) biosimilar.
On this episode of Not So Different, we reminisced about the major biosimilar news to come out of the rheumatology field during January 2023, including the launch of the first Humira (adalimumab) biosimilar.
Show notes
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Canada Approves High-Concentration Humira Biosimilar
https://www.centerforbiosimilars.com/view/canada-approves-high-concentration-humira-biosimilar
Celltrion Submits BLA for Infliximab Biobetter
https://www.centerforbiosimilars.com/view/celltrion-submits-bla-for-infliximab-biobetter
FDA Accepts BLA for Alvotech Ustekinumab Biosimilar
https://www.centerforbiosimilars.com/view/fda-accepts-bla-for-alvotech-ustekinumab-biosimilar
Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study
China's NMPA Approves Tocilizumab Biosimilar
https://www.centerforbiosimilars.com/view/china-s-nmpa-approves-tocilizumab-biosimilar
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Study: Does Adalimumab Lose Effectiveness After Switching to a Biosimilar?
Phase 1 Trial for Alvotech Golimumab Biosimilar Begins
https://www.centerforbiosimilars.com/view/phase-1-trial-for-alvotech-golimumab-biosimilar-begins
Case Study: Treatment With Adalimumab Biosimilar Resolved Pediatric Scalp, Nail Psoriasis
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.